142P Long-term follow-up of neoadjuvant dual anti-HER2 therapy with trastuzumab and lapatinib plus paclitaxel, with or without endocrine therapy for HER2-positive primary breast cancer: Neo-LaTH (JBCRG-16) study.
Saved in:
| Title: | 142P Long-term follow-up of neoadjuvant dual anti-HER2 therapy with trastuzumab and lapatinib plus paclitaxel, with or without endocrine therapy for HER2-positive primary breast cancer: Neo-LaTH (JBCRG-16) study. |
|---|---|
| Authors: | Fujisawa, T.1 (AUTHOR), Masuda, N.2 (AUTHOR), Yamamoto, N.3 (AUTHOR), Iwata, H.4 (AUTHOR), Bando, H.5 (AUTHOR), Aruga, T.6 (AUTHOR), Tokunaga, E.7 (AUTHOR), Ohtani, S.8 (AUTHOR), Takano, T.9 (AUTHOR), Inoue, K.10 (AUTHOR), Suganuma, N.11 (AUTHOR), Takada, M.12 (AUTHOR), Aogi, K.13 (AUTHOR), Sakurai, K.14 (AUTHOR), Shigematsu, H.15 (AUTHOR), Kuroi, K.16 (AUTHOR), Haga, H.17 (AUTHOR), Ohno, S.18 (AUTHOR), Morita, S.19 (AUTHOR), Toi, M.20 (AUTHOR) |
| Source: | Annals of Oncology. 2021 Supplement 5, Vol. 32, pS422-S422. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2021.08.423 |
